Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colon Cancer Adjuvant Trials Need 3-Year Disease-Free Survival – FDA Cmte

Executive Summary

Three-year disease-free survival is an adequate endpoint for standard approval of a colorectal cancer agent in the adjuvant setting, FDA's Oncologic Drugs Advisory Committee concluded May 4

You may also be interested in...



Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival

Progression-free survival is an acceptable basis for accelerated approval of ovarian cancer agents, so long as trials are powered for survival, panelists at FDA's April 26 Ovarian Cancer Endpoint Workshop in Bethesda, Md. said

Ovarian Progression-Free Survival Acceptable If Trial Is Powered For Survival

Progression-free survival is an acceptable basis for accelerated approval of ovarian cancer agents, so long as trials are powered for survival, panelists at FDA's April 26 Ovarian Cancer Endpoint Workshop in Bethesda, Md. said

Progression-Free Survival Must Be Tied To Survival For Oncologic Approval

Progression-free survival will have to be validated as a surrogate for survival on a cancer-by-cancer basis for PFS to be considered as a valid endpoint for approval, comments by FDA and members of its Oncologic Drugs Advisory Committee suggest

Related Content

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel